Cellectis CLLS
NASDAQ CLLS
$3.24 -0.08 (-2.41%)
At close: Sep 4, 2026 · 4:00 PM EDT

Cellectis (CLLS) Other Non-Current Liabilities (2015 - 2024)

Cellectis (CLLS) posted quarterly Other Non-Current Liabilities of $1.3 million for Q1 2026, up 16.24% year-over-year from $1.1 million in Q1 2025, and little changed quarter-over-quarter from $1.3 million in Q4 2025.

Analysis

Cellectis (CLLS) Other Non-Current Liabilities (2015 - 2024) Analysis & Trends

Cellectis' Other Non-Current Liabilities history runs 13 years deep, the most recent figure standing at $1.3 million for Q1 2026.

  • In Q1 2026, Other Non-Current Liabilities rose 16.24% year-over-year to $1.3 million; the TTM figure through Mar 2026 stood at $1.3 million (up 16.24% YoY), while the FY2025 annual figure was $1.3 million, up 19.19% from the prior year.
  • Other Non-Current Liabilities for Q1 2026 stood at $1.3 million, roughly flat from $1.3 million in the prior quarter.
  • The five-year high for Other Non-Current Liabilities was $3.7 million in Q1 2022, with the low at $1.1 million in Q4 2024.
  • The 5-year median for Other Non-Current Liabilities is $2.2 million (2024), against an average of $2.1 million.
  • The sharpest annual moves came in 2024 and 2025: Other Non-Current Liabilities tumbled 49.32% in 2024, then advanced 19.19% in 2025.
  • Cellectis' Other Non-Current Liabilities stood at $2.4 million in 2022, then slipped by 7.95% to $2.2 million in 2023, then sank by 49.32% to $1.1 million in 2024, then increased by 19.19% to $1.3 million in 2025, then fell by 0.38% to $1.3 million in 2026.
  • Business Quant data shows CLLS's Other Non-Current Liabilities at $1.3 million in Q1 2026, $1.3 million in Q4 2025, and $1.3 million in Q3 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn
10 Cellectis 321.90 Mn 155.05 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2024 138.58 Mn
Dec 31, 2023 135.15 Mn
Mar 31, 2023 13.21 Mn
Mar 31, 2022 73,000.00
Dec 31, 2021 626,000.00
Sep 30, 2021 787,000.00
Jun 30, 2021 948,000.00
Mar 31, 2021 1.11 Mn
Dec 31, 2015 23.34 Mn